Participants in the study will be randomly assigned to receive either MK-0616 or a placebo. The study will last for a total of 52 weeks, with the main focus on changes in low-density lipoprotein cholesterol (LDL-C) levels at Week 24. LDL-C is often referred to as “bad” cholesterol because high levels can lead to the buildup of cholesterol in arteries. The study will also monitor the safety and any side effects experienced by participants during this period.

Throughout the study, participants will have regular check-ups to monitor their cholesterol levels and overall health. The study aims to provide valuable information on whether MK-0616 can effectively lower cholesterol levels and improve heart health in individuals with hypercholesterolemia. This research could potentially lead to new treatment options for managing high cholesterol and reducing the risk of heart-related complications.

Participants in the study will receive either the test drug, a comparator medication, or a placebo. The study period lasts for 12 weeks, during which the effects on LDL-C, which is often referred to as bad cholesterol, will be monitored. Other substances in the blood, such as HDL-C, triglycerides, and total cholesterol, may also be observed to see how they change during the course of the treatment.

The purpose of this research is to determine how well AZD0780 works compared to placebo in lowering LDL cholesterol levels after 12 weeks of treatment. The medication comes as a film-coated tablet that is taken by mouth. Some participants will receive AZD0780, while others will receive a placebo.

The study will last for 52 weeks (one year), during which participants will continue taking their regular cholesterol-lowering medications. Throughout the study, researchers will measure various types of cholesterol and other blood fats, including apolipoprotein B, non-HDL cholesterol, and lipoprotein(a), to understand how well the treatment works.

Participants in the study will be randomly assigned to receive either MK-0616, Ezetimibe, Bempedoic Acid, or a combination of Ezetimibe and Bempedoic Acid. Some participants may receive a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment each participant is receiving, to ensure unbiased results. The treatments will be taken orally, and the study will monitor changes in cholesterol levels and any side effects experienced by participants.

The main goal is to measure the change in LDL-C levels from the start of the study to Day 56. Secondary goals include observing changes in other cholesterol-related markers and the number of participants who achieve specific cholesterol level targets. The study will also track any adverse events, which are unwanted effects that may occur during the trial. This research aims to provide valuable information on the effectiveness of MK-0616 compared to existing treatments for managing high cholesterol.

Participants in this study will continue to take the MK-0616 tablet as part of an open-label extension, meaning that both the participants and the researchers know what treatment is being administered. The study will monitor participants for any adverse events, which are any unwanted effects that may occur during the trial. Additionally, the study will assess changes in cholesterol levels, specifically looking at low-density lipoprotein cholesterol (LDL-C), which is often referred to as “bad” cholesterol, and other related markers.

The trial is designed to last for several years, allowing researchers to gather comprehensive data on the long-term effects of MK-0616. Participants will be regularly monitored to ensure their safety and to track the effectiveness of the treatment in managing their cholesterol levels. This study aims to provide valuable information on how well MK-0616 works and how safe it is for people with high cholesterol.

The purpose of the study is to understand how Bempedoic acid works in children aged 6 to 17 who have HeFH. The study will look at how the body processes the medication and how it affects cholesterol levels. Participants will take the medication once daily for a period of 8 weeks. During this time, researchers will monitor the levels of the medication in the blood and observe any changes in cholesterol levels. The study will also assess how well children tolerate the medication, including its taste and ease of swallowing.

This study is important because it aims to provide more information about the safety and effectiveness of Bempedoic acid in young patients with HeFH. By understanding how the medication works in children, researchers hope to find better ways to manage high cholesterol levels in this age group. The study is expected to continue until 2025, allowing enough time to gather comprehensive data on the medication’s effects.

The purpose of the study is to evaluate whether using genetic information can help reduce muscle-related side effects in patients taking statins. Some people experience muscle pain or weakness when taking statins, and this study aims to see if genetic testing can help doctors choose the right statin for each patient to minimize these side effects. The study will compare two groups of patients: one group will receive statins based on standard medical practice, while the other group will have their statin prescribed based on genetic testing results. The study will follow participants for six months to observe any differences in muscle-related side effects between the two groups.

Participants in the study will be adults who need statins to manage their cardiovascular risk. They will be monitored for any muscle-related side effects during the first six months of treatment, with some participants being followed for up to a year or longer. The study aims to provide valuable insights into how genetic testing can be used to improve the safety and effectiveness of statin therapy in managing cardiovascular risk.

Participants in the study will receive either evolocumab, which is also known by its code name AMG145, or a placebo, in addition to their regular cholesterol management. Evolocumab is given through an injection under the skin using a device called an autoinjector pen. The study will monitor participants over a period to observe any changes in their health, particularly focusing on the occurrence of heart attacks, strokes, and other cardiovascular events.

The purpose of this study is to determine if evolocumab, when used early during hospitalization for a heart attack, can effectively lower the risk of future cardiovascular events compared to standard cholesterol management alone. The study will also look at changes in cholesterol levels over time in a subset of participants. This research is important for understanding how to better protect heart health in patients who have experienced a heart attack.

The purpose of the study is to determine if Inclisiran is more effective than bempedoic acid in reducing LDL cholesterol levels over a period of 150 days. Participants will be randomly assigned to receive one of the treatments and will be monitored throughout the study to assess changes in their cholesterol levels. The study will also look at how well participants respond to the treatments, aiming for LDL cholesterol levels to reach specific targets based on their risk of heart disease.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. The study is designed to provide valuable information on how these medications can help manage cholesterol levels in people with atherosclerotic cardiovascular disease, potentially leading to better treatment options in the future. A placebo may be used in some cases to compare the effects of the active treatments. The study is expected to conclude in 2025.

The purpose of the study is to determine if Inclisiran, when added to ongoing cholesterol-lowering therapy, is more effective than a placebo in helping participants reach their individual cholesterol targets. The study will also assess the safety of Inclisiran and its impact on the quality of life of participants. Participants will be randomly assigned to receive either Inclisiran or a placebo, in addition to their regular cholesterol-lowering medication, and will be monitored over a period of time to observe changes in their cholesterol levels and any side effects.

Throughout the study, participants will have regular check-ups to monitor their cholesterol levels and overall health. The study aims to provide valuable information on whether Inclisiran can offer additional benefits in managing cholesterol levels and improving the quality of life for individuals with hypercholesterolemia. The results will help determine the effectiveness and safety of Inclisiran as part of a comprehensive cholesterol-lowering treatment plan.

Participants in the study will be randomly assigned to receive either the MK-0616 treatment or a placebo, which is a substance with no active medication. The study will last for a total of 52 weeks, with key assessments taking place at Week 24 and Week 52. During this time, the main focus will be on observing changes in the levels of low-density lipoprotein cholesterol (often referred to as “bad” cholesterol) in the participants’ blood. Additionally, the study will monitor any side effects or adverse events that participants may experience.

The trial aims to provide valuable information on whether MK-0616 can effectively lower cholesterol levels and improve the health of individuals with Hypercholesterolemia. By the end of the study, researchers hope to determine if this treatment can be a safe and beneficial option for managing high cholesterol.